Latest Financial Results

Q2 2019

Quarterly Results

Ended Apr 30, 2019

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.

Logo Itus

Latest News & Events

Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology

Read More...

Anixa Biosciences Highlights Recent Publication in The Journal of Experimental Medicine on Myeloid Derived Suppressor Cells

Read More...

Anixa Biosciences to Present at the CYTO 2019 - 34th Congress of the International Society for Advancement of Cytometry

Read More...

Cancer Fact: Approximately 40 million mammograms are conducted annually.